CLIA Waived Molecular Rapid Flu Test from Alere.

The Alere™ i Influenza A & B test revolutionizes rapid flu testing by providing highly accurate, molecular results in less than 15 minutes on the user-friendly Alere™ i platform. A rapid, molecular flu result with Alere™ i Influenza A & B empowers you to transform patient care in any setting.

Alere™ i Influenza A & B

• Gives you confidence to make appropriate clinical decisions sooner
• Enables prompt initiation of infection control measures
• Aids targeted antiviral therapy and Antimicrobial Stewardship
• Allows you to respond quickly and accurately in any setting
• With a positive result, you can test and treat in a single patient visit

Outstanding Performance

Alere™ i Influenza A & B vs. PCR

   PPA: Positive Percent Agreement
    NPA: Negative Percent Agreement

Alere™ i Influenza A & B Performance vs. Culture

   a. Flu A nucleic acid was detected in 58/66 False Positive specimens using an FDA-cleared molecular test.
   b. Flu A nucleic acid was not detected in 1/2 False Negative specimens using an FDA-cleared molecular test.
   c. Flu B nucleic acid was detected in 15/17 False Positive specimens using an FDA-cleared molecular test.
   d. Flu B nucleic acid was not detected in 4/6 False Negative specimens using an FDA-cleared molecular test.

A new level of confidence in test sensitivity²,³

Faster than other molecular methods

The Alere™ i Influenza A & B kit contains all components required to carry out an assay for influenza A and B on the Alere™ i instrument. It tests for the qualitative detection and differentiation of influenza A and influenza B from nasal swab samples and viral transport media.

For more detail: https://www.news-medical.net/ads/abmc.aspx?b=1918